Bvf Inc Selecta Biosciences Inc Transaction History

Bvf Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.33 - $2.6 $440,740 - $861,598	-331,384 Reduced 19.23%	1,391,749 $2.28 Million
Q4 2021 Feb 14, 2022	BUY	$2.89 - $4.43 $4.06 Million - $6.22 Million	1,403,455 Added 439.02%	1,723,133 $5.62 Million
Q3 2021 Nov 15, 2021	SELL	$3.36 - $4.62 $4.62 Million - $6.35 Million	-1,373,778 Reduced 81.12%	319,678 $1.33 Million
Q2 2021 Aug 16, 2021	SELL	$2.82 - $5.01 $1.94 Million - $3.44 Million	-686,530 Reduced 28.85%	1,693,456 $7.08 Million
Q1 2021 May 17, 2021	SELL	$2.92 - $5.07 $2.7 Million - $4.69 Million	-924,977 Reduced 27.99%	2,379,986 $10.8 Million
Q4 2020 Feb 12, 2021	SELL	$1.64 - $3.42 $8.45 Million - $17.6 Million	-5,154,584 Reduced 60.93%	3,304,963 $10 Million
Q3 2020 Nov 13, 2020	BUY	$2.18 - $2.84 $359,700 - $468,600	165,000 Added 1.99%	8,459,547 $21 Million
Q2 2020 Aug 14, 2020	BUY	$1.83 - $4.06 $8.57 Million - $19 Million	4,685,075 Added 129.8%	8,294,547 $23.6 Million
Q1 2020 May 15, 2020	BUY	$1.5 - $4.52 $488,100 - $1.47 Million	325,400 Added 9.91%	3,609,472 $8.7 Million
Q4 2019 Feb 14, 2020	BUY	$1.32 - $2.47 $4.33 Million - $8.11 Million	3,284,072 New	3,284,072 $7.82 Million

4.67M

Ticker SELB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 152,712,992
Market Cap $128M
Description
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. I...

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

Stay updated on Bvf Inc with notifications on news.